| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Models, Statistical | 66 | 2022 | 5098 | 4.080 |
Why?
|
| Causality | 29 | 2024 | 1253 | 3.070 |
Why?
|
| Data Interpretation, Statistical | 33 | 2022 | 2698 | 2.660 |
Why?
|
| Epidemiologic Methods | 27 | 2013 | 1326 | 1.940 |
Why?
|
| Probability | 21 | 2012 | 2476 | 1.080 |
Why?
|
| Epidemiologic Research Design | 5 | 2017 | 368 | 1.000 |
Why?
|
| Biometry | 13 | 2010 | 571 | 0.990 |
Why?
|
| Randomized Controlled Trials as Topic | 23 | 2021 | 10393 | 0.960 |
Why?
|
| Estrogen Replacement Therapy | 4 | 2016 | 1209 | 0.910 |
Why?
|
| Research Design | 17 | 2023 | 6210 | 0.870 |
Why?
|
| Antiretroviral Therapy, Highly Active | 10 | 2015 | 1902 | 0.840 |
Why?
|
| Nose Neoplasms | 2 | 2023 | 250 | 0.830 |
Why?
|
| Cavernous Sinus | 1 | 2023 | 121 | 0.800 |
Why?
|
| Acquired Immunodeficiency Syndrome | 11 | 2011 | 2204 | 0.790 |
Why?
|
| Zidovudine | 7 | 2004 | 625 | 0.780 |
Why?
|
| Decompressive Craniectomy | 1 | 2020 | 76 | 0.670 |
Why?
|
| Epidemiologic Studies | 4 | 2010 | 677 | 0.660 |
Why?
|
| Braces | 1 | 2020 | 139 | 0.660 |
Why?
|
| Patient Dropouts | 3 | 2012 | 411 | 0.660 |
Why?
|
| CD4 Lymphocyte Count | 19 | 2019 | 2586 | 0.630 |
Why?
|
| Intention to Treat Analysis | 2 | 2017 | 418 | 0.630 |
Why?
|
| Selection Bias | 7 | 2015 | 360 | 0.610 |
Why?
|
| Regression Analysis | 11 | 2018 | 6331 | 0.590 |
Why?
|
| Anti-HIV Agents | 15 | 2019 | 4567 | 0.580 |
Why?
|
| Likelihood Functions | 5 | 2018 | 996 | 0.580 |
Why?
|
| Sphenoid Sinus | 1 | 2017 | 101 | 0.560 |
Why?
|
| Progestins | 2 | 2016 | 302 | 0.510 |
Why?
|
| Clinical Trials as Topic | 7 | 2012 | 8048 | 0.510 |
Why?
|
| Survival Analysis | 15 | 2020 | 10092 | 0.510 |
Why?
|
| Craniosynostoses | 1 | 2020 | 415 | 0.500 |
Why?
|
| Computer Graphics | 2 | 2007 | 345 | 0.500 |
Why?
|
| Cerebral Palsy | 1 | 2020 | 480 | 0.490 |
Why?
|
| Mortality | 4 | 2017 | 2909 | 0.480 |
Why?
|
| HIV Infections | 22 | 2019 | 17542 | 0.480 |
Why?
|
| Air Pollution | 2 | 2022 | 2378 | 0.470 |
Why?
|
| Bayes Theorem | 8 | 2017 | 2353 | 0.470 |
Why?
|
| Comparative Effectiveness Research | 3 | 2016 | 713 | 0.460 |
Why?
|
| Endoscopy | 4 | 2022 | 1854 | 0.460 |
Why?
|
| Observation | 4 | 2017 | 310 | 0.430 |
Why?
|
| Personnel, Hospital | 1 | 2015 | 285 | 0.430 |
Why?
|
| Pituitary Neoplasms | 2 | 2021 | 1322 | 0.420 |
Why?
|
| Disease Outbreaks | 5 | 2008 | 1761 | 0.390 |
Why?
|
| Viral Load | 10 | 2019 | 3385 | 0.390 |
Why?
|
| Clinical Protocols | 1 | 2017 | 1443 | 0.380 |
Why?
|
| Statistics as Topic | 12 | 2016 | 2350 | 0.370 |
Why?
|
| Adenoma | 2 | 2021 | 2155 | 0.360 |
Why?
|
| Vaccines | 3 | 2023 | 842 | 0.350 |
Why?
|
| Vietnam Conflict | 1 | 2010 | 100 | 0.340 |
Why?
|
| Cross-Over Studies | 3 | 2022 | 2105 | 0.340 |
Why?
|
| Humans | 151 | 2024 | 767040 | 0.330 |
Why?
|
| Treatment Refusal | 4 | 2006 | 433 | 0.320 |
Why?
|
| Computer Simulation | 13 | 2021 | 6260 | 0.320 |
Why?
|
| Communicable Diseases | 2 | 2008 | 872 | 0.320 |
Why?
|
| Longitudinal Studies | 17 | 2022 | 14766 | 0.320 |
Why?
|
| Heroin Dependence | 1 | 2010 | 173 | 0.320 |
Why?
|
| Weight Gain | 3 | 2020 | 2360 | 0.300 |
Why?
|
| HIV-1 | 9 | 2017 | 6951 | 0.290 |
Why?
|
| Anti-Retroviral Agents | 3 | 2015 | 1787 | 0.280 |
Why?
|
| Cholesterol, LDL | 1 | 2016 | 2392 | 0.270 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2012 | 1040 | 0.260 |
Why?
|
| RNA, Viral | 3 | 2019 | 2867 | 0.250 |
Why?
|
| Pneumonia, Pneumocystis | 2 | 2000 | 242 | 0.250 |
Why?
|
| Case-Control Studies | 12 | 2024 | 22254 | 0.250 |
Why?
|
| Linear Models | 3 | 2007 | 5875 | 0.220 |
Why?
|
| Cranial Fossa, Middle | 1 | 2023 | 29 | 0.220 |
Why?
|
| Benzoxazines | 2 | 2016 | 320 | 0.210 |
Why?
|
| Proportional Hazards Models | 12 | 2011 | 12536 | 0.210 |
Why?
|
| Stroke | 3 | 2020 | 9746 | 0.200 |
Why?
|
| Pharmacoepidemiology | 1 | 2006 | 351 | 0.200 |
Why?
|
| Biostatistics | 1 | 2024 | 162 | 0.200 |
Why?
|
| Epidemiology | 4 | 1989 | 278 | 0.200 |
Why?
|
| Mathematics | 8 | 2009 | 696 | 0.200 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2016 | 3249 | 0.200 |
Why?
|
| Drug Monitoring | 2 | 2019 | 963 | 0.190 |
Why?
|
| Particulate Matter | 1 | 2013 | 2621 | 0.190 |
Why?
|
| Risk | 12 | 1999 | 9606 | 0.190 |
Why?
|
| Decision Making | 4 | 2019 | 3951 | 0.190 |
Why?
|
| Citrus sinensis | 1 | 2020 | 15 | 0.180 |
Why?
|
| Smoking Cessation | 3 | 2020 | 2085 | 0.180 |
Why?
|
| Dementia | 1 | 2015 | 2741 | 0.180 |
Why?
|
| Stochastic Processes | 5 | 2008 | 359 | 0.180 |
Why?
|
| Pituitary Hormones | 1 | 2021 | 182 | 0.170 |
Why?
|
| Rhizotomy | 1 | 2020 | 30 | 0.170 |
Why?
|
| Malus | 1 | 2020 | 51 | 0.170 |
Why?
|
| Comorbidity | 5 | 2013 | 10582 | 0.170 |
Why?
|
| Environmental Exposure | 6 | 2004 | 4546 | 0.170 |
Why?
|
| Air Pollutants | 2 | 2013 | 2920 | 0.170 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2005 | 1164 | 0.170 |
Why?
|
| Statistics, Nonparametric | 5 | 2006 | 2850 | 0.170 |
Why?
|
| Frontal Bone | 1 | 2020 | 105 | 0.170 |
Why?
|
| Visual Field Tests | 1 | 2022 | 415 | 0.170 |
Why?
|
| Multicenter Studies as Topic | 4 | 2007 | 1733 | 0.170 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 404 | 0.160 |
Why?
|
| HIV Seropositivity | 2 | 2016 | 963 | 0.160 |
Why?
|
| Models, Theoretical | 5 | 2017 | 3561 | 0.160 |
Why?
|
| Craniotomy | 1 | 2023 | 736 | 0.160 |
Why?
|
| Quality of Life | 2 | 2020 | 13485 | 0.150 |
Why?
|
| Coronary Disease | 4 | 2016 | 5914 | 0.150 |
Why?
|
| Models, Genetic | 3 | 2007 | 3445 | 0.150 |
Why?
|
| Logistic Models | 6 | 2013 | 13284 | 0.150 |
Why?
|
| Female | 48 | 2024 | 396660 | 0.150 |
Why?
|
| Therapeutic Equivalency | 1 | 1998 | 135 | 0.150 |
Why?
|
| Educational Status | 1 | 2005 | 2511 | 0.140 |
Why?
|
| Patient Simulation | 1 | 2020 | 300 | 0.140 |
Why?
|
| Genetics | 1 | 1998 | 114 | 0.140 |
Why?
|
| Occupational Diseases | 7 | 1989 | 1456 | 0.140 |
Why?
|
| Time Factors | 18 | 2018 | 40154 | 0.140 |
Why?
|
| Breast Neoplasms | 7 | 2016 | 21178 | 0.140 |
Why?
|
| Models, Biological | 4 | 2007 | 9464 | 0.140 |
Why?
|
| Treatment Outcome | 18 | 2020 | 65295 | 0.140 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2000 | 663 | 0.140 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2018 | 186 | 0.140 |
Why?
|
| Orbit | 1 | 2020 | 459 | 0.140 |
Why?
|
| Linkage Disequilibrium | 1 | 2001 | 1996 | 0.130 |
Why?
|
| Medroxyprogesterone | 1 | 2016 | 34 | 0.130 |
Why?
|
| AIDS-Related Complex | 1 | 2016 | 107 | 0.130 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 6573 | 0.130 |
Why?
|
| Evaluation Studies as Topic | 2 | 2012 | 1623 | 0.130 |
Why?
|
| Cardiovascular Diseases | 5 | 2024 | 15645 | 0.130 |
Why?
|
| Fibrinolytic Agents | 1 | 2005 | 2079 | 0.130 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 1012 | 0.130 |
Why?
|
| Learning Curve | 1 | 2017 | 232 | 0.130 |
Why?
|
| Influenza, Human | 4 | 2010 | 1543 | 0.130 |
Why?
|
| Male | 46 | 2024 | 364203 | 0.120 |
Why?
|
| Drug Therapy, Combination | 5 | 2016 | 6310 | 0.120 |
Why?
|
| Drug Administration Schedule | 5 | 2012 | 4855 | 0.120 |
Why?
|
| Visual Fields | 1 | 2022 | 1063 | 0.120 |
Why?
|
| Education, Nursing | 1 | 2015 | 83 | 0.120 |
Why?
|
| Bone Transplantation | 1 | 2020 | 921 | 0.120 |
Why?
|
| Sarcoma, Kaposi | 1 | 1998 | 376 | 0.120 |
Why?
|
| Forced Expiratory Volume | 3 | 1992 | 1830 | 0.120 |
Why?
|
| Critical Illness | 1 | 2007 | 2753 | 0.120 |
Why?
|
| Nonlinear Dynamics | 1 | 1997 | 490 | 0.110 |
Why?
|
| Algorithms | 9 | 2010 | 14098 | 0.110 |
Why?
|
| Bariatric Surgery | 1 | 2024 | 998 | 0.110 |
Why?
|
| Ecology | 1 | 1994 | 105 | 0.110 |
Why?
|
| Chromosome Mapping | 1 | 2001 | 4616 | 0.110 |
Why?
|
| United States | 17 | 2024 | 72971 | 0.110 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2016 | 620 | 0.110 |
Why?
|
| Thrombophlebitis | 1 | 1993 | 289 | 0.100 |
Why?
|
| Middle Aged | 33 | 2024 | 223233 | 0.100 |
Why?
|
| Risk Factors | 20 | 2020 | 74886 | 0.100 |
Why?
|
| Brain Ischemia | 1 | 2005 | 3001 | 0.100 |
Why?
|
| Neurosurgical Procedures | 1 | 2023 | 2075 | 0.100 |
Why?
|
| Dermoid Cyst | 1 | 2013 | 92 | 0.100 |
Why?
|
| Health Status | 1 | 2005 | 4091 | 0.100 |
Why?
|
| Cohort Studies | 13 | 2016 | 41718 | 0.100 |
Why?
|
| Developed Countries | 4 | 2017 | 453 | 0.100 |
Why?
|
| Life Style | 3 | 2020 | 3931 | 0.100 |
Why?
|
| Adult | 38 | 2024 | 223317 | 0.100 |
Why?
|
| Confidence Intervals | 3 | 2010 | 2920 | 0.100 |
Why?
|
| Hospital Mortality | 1 | 2005 | 5345 | 0.100 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2012 | 214 | 0.090 |
Why?
|
| Tumor Burden | 1 | 2017 | 1903 | 0.090 |
Why?
|
| Job Satisfaction | 1 | 2015 | 548 | 0.090 |
Why?
|
| Cause of Death | 6 | 2017 | 3717 | 0.090 |
Why?
|
| Europe | 5 | 2017 | 3432 | 0.090 |
Why?
|
| Sample Size | 2 | 2021 | 845 | 0.090 |
Why?
|
| Nevirapine | 1 | 2012 | 273 | 0.090 |
Why?
|
| Hydrocephalus | 1 | 2018 | 766 | 0.090 |
Why?
|
| Postmenopause | 2 | 2016 | 2518 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2005 | 3968 | 0.090 |
Why?
|
| Military Personnel | 1 | 2020 | 1261 | 0.090 |
Why?
|
| Exercise | 5 | 2020 | 5954 | 0.090 |
Why?
|
| Forecasting | 1 | 2020 | 2936 | 0.090 |
Why?
|
| Oseltamivir | 1 | 2010 | 76 | 0.090 |
Why?
|
| Scalp | 1 | 2013 | 390 | 0.080 |
Why?
|
| Fishes | 1 | 2013 | 607 | 0.080 |
Why?
|
| Family Characteristics | 2 | 2012 | 1002 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2002 | 4405 | 0.080 |
Why?
|
| Patient Compliance | 2 | 2017 | 2697 | 0.080 |
Why?
|
| Mathematical Computing | 2 | 2007 | 142 | 0.080 |
Why?
|
| Smoking | 11 | 2013 | 9081 | 0.080 |
Why?
|
| Nose | 1 | 2013 | 522 | 0.080 |
Why?
|
| Obesity | 3 | 2018 | 13085 | 0.080 |
Why?
|
| Adolescent | 7 | 2023 | 89046 | 0.080 |
Why?
|
| Emergency Medical Services | 1 | 2020 | 1936 | 0.080 |
Why?
|
| Epistasis, Genetic | 1 | 2010 | 353 | 0.080 |
Why?
|
| Propensity Score | 1 | 2016 | 1971 | 0.070 |
Why?
|
| Mass Screening | 1 | 2004 | 5456 | 0.070 |
Why?
|
| Incidence | 5 | 2021 | 21526 | 0.070 |
Why?
|
| Data Collection | 3 | 2001 | 3321 | 0.070 |
Why?
|
| Random Allocation | 6 | 1990 | 2394 | 0.070 |
Why?
|
| Sensitivity and Specificity | 5 | 2004 | 14672 | 0.070 |
Why?
|
| Postoperative Complications | 2 | 2021 | 15824 | 0.070 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2008 | 277 | 0.070 |
Why?
|
| Population Density | 1 | 2007 | 193 | 0.070 |
Why?
|
| Chicago | 1 | 2007 | 255 | 0.070 |
Why?
|
| Temperature | 1 | 2013 | 2232 | 0.070 |
Why?
|
| Life Expectancy | 2 | 1991 | 1248 | 0.070 |
Why?
|
| Mining | 1 | 1987 | 93 | 0.070 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 453 | 0.070 |
Why?
|
| Weight Loss | 2 | 2016 | 2716 | 0.070 |
Why?
|
| Odds Ratio | 5 | 2010 | 9660 | 0.070 |
Why?
|
| Heparin | 1 | 1993 | 1636 | 0.070 |
Why?
|
| Disease | 2 | 2004 | 675 | 0.060 |
Why?
|
| Disease Transmission, Infectious | 2 | 2010 | 560 | 0.060 |
Why?
|
| Feeding Behavior | 2 | 2020 | 3207 | 0.060 |
Why?
|
| Genetic Markers | 1 | 2012 | 2602 | 0.060 |
Why?
|
| Urban Population | 1 | 2013 | 2044 | 0.060 |
Why?
|
| Analysis of Variance | 4 | 2004 | 6215 | 0.060 |
Why?
|
| Estrogens | 2 | 2010 | 1536 | 0.060 |
Why?
|
| Diet | 3 | 2018 | 8089 | 0.060 |
Why?
|
| Survival Rate | 4 | 2013 | 12823 | 0.060 |
Why?
|
| Follow-Up Studies | 9 | 2021 | 39317 | 0.060 |
Why?
|
| Bulimia | 1 | 2007 | 405 | 0.060 |
Why?
|
| Body Mass Index | 3 | 2016 | 13048 | 0.060 |
Why?
|
| Reproducibility of Results | 4 | 2012 | 20169 | 0.060 |
Why?
|
| Prospective Studies | 11 | 2017 | 54886 | 0.060 |
Why?
|
| Double-Blind Method | 4 | 2010 | 12451 | 0.060 |
Why?
|
| Environment | 1 | 2010 | 1120 | 0.060 |
Why?
|
| History, 20th Century | 2 | 2010 | 2765 | 0.060 |
Why?
|
| Monte Carlo Method | 3 | 2017 | 1250 | 0.060 |
Why?
|
| Child Development | 2 | 2006 | 2329 | 0.060 |
Why?
|
| Cyanates | 1 | 1983 | 22 | 0.060 |
Why?
|
| Toluene 2,4-Diisocyanate | 1 | 1983 | 13 | 0.060 |
Why?
|
| Alkynes | 2 | 2016 | 326 | 0.060 |
Why?
|
| Length of Stay | 1 | 2017 | 6489 | 0.050 |
Why?
|
| Didanosine | 1 | 2003 | 151 | 0.050 |
Why?
|
| Veterans | 2 | 2024 | 2666 | 0.050 |
Why?
|
| Markov Chains | 2 | 2017 | 976 | 0.050 |
Why?
|
| Germany | 1 | 2005 | 882 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2001 | 2658 | 0.050 |
Why?
|
| Child | 4 | 2020 | 80771 | 0.050 |
Why?
|
| Cyclopropanes | 2 | 2016 | 436 | 0.050 |
Why?
|
| Homosexuality, Male | 2 | 2004 | 1344 | 0.050 |
Why?
|
| Child, Preschool | 5 | 2020 | 42606 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 9410 | 0.050 |
Why?
|
| Motor Skills | 1 | 2006 | 521 | 0.050 |
Why?
|
| Nervous System | 1 | 2006 | 543 | 0.050 |
Why?
|
| Research Subjects | 1 | 2004 | 249 | 0.050 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2003 | 136 | 0.050 |
Why?
|
| Hormone Replacement Therapy | 2 | 2013 | 756 | 0.050 |
Why?
|
| Infant | 4 | 2020 | 36485 | 0.050 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 5180 | 0.050 |
Why?
|
| Premature Birth | 1 | 2014 | 1830 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 3928 | 0.050 |
Why?
|
| Myocardial Infarction | 3 | 2005 | 11513 | 0.050 |
Why?
|
| Air Pollutants, Occupational | 3 | 1989 | 406 | 0.050 |
Why?
|
| Pentamidine | 1 | 2000 | 44 | 0.040 |
Why?
|
| Public Health Practice | 1 | 2003 | 220 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 1791 | 0.040 |
Why?
|
| Hypertension | 2 | 1998 | 8615 | 0.040 |
Why?
|
| Risk Assessment | 4 | 2017 | 24299 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2016 | 8068 | 0.040 |
Why?
|
| Carbon Compounds, Inorganic | 2 | 1989 | 12 | 0.040 |
Why?
|
| Silicon Compounds | 2 | 1989 | 16 | 0.040 |
Why?
|
| Heart | 1 | 1993 | 4429 | 0.040 |
Why?
|
| Aged | 13 | 2021 | 171319 | 0.040 |
Why?
|
| Pituitary Gland | 1 | 2022 | 635 | 0.040 |
Why?
|
| Silicon | 2 | 1989 | 141 | 0.040 |
Why?
|
| Risperidone | 1 | 2001 | 383 | 0.040 |
Why?
|
| Penetrance | 1 | 2000 | 388 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2000 | 18063 | 0.040 |
Why?
|
| Boston | 2 | 2007 | 9360 | 0.040 |
Why?
|
| Graft vs Leukemia Effect | 1 | 1999 | 121 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 1998 | 5859 | 0.040 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2006 | 1354 | 0.040 |
Why?
|
| Health Surveys | 1 | 2008 | 4056 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2010 | 2191 | 0.040 |
Why?
|
| Time | 1 | 2020 | 551 | 0.040 |
Why?
|
| Prenatal Care | 1 | 2006 | 1158 | 0.040 |
Why?
|
| Isoniazid | 1 | 1999 | 279 | 0.040 |
Why?
|
| Infant, Newborn | 4 | 2014 | 26396 | 0.040 |
Why?
|
| Eye | 1 | 2022 | 711 | 0.040 |
Why?
|
| Models, Structural | 1 | 1998 | 339 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2010 | 3070 | 0.040 |
Why?
|
| Aerosols | 1 | 2000 | 634 | 0.040 |
Why?
|
| Public Health | 1 | 1991 | 2681 | 0.040 |
Why?
|
| Vitamins | 1 | 2006 | 1639 | 0.040 |
Why?
|
| Proteins | 1 | 2012 | 6001 | 0.030 |
Why?
|
| Disease Progression | 4 | 2011 | 13646 | 0.030 |
Why?
|
| Developmental Disabilities | 1 | 2006 | 1518 | 0.030 |
Why?
|
| Homozygote | 1 | 2001 | 1774 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2004 | 2721 | 0.030 |
Why?
|
| Retrospective Studies | 5 | 2021 | 81659 | 0.030 |
Why?
|
| Systems Analysis | 1 | 2017 | 168 | 0.030 |
Why?
|
| Family | 1 | 2007 | 3210 | 0.030 |
Why?
|
| Pregnancy | 4 | 2014 | 30238 | 0.030 |
Why?
|
| Respiration Disorders | 2 | 1989 | 364 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2004 | 1794 | 0.030 |
Why?
|
| Bisexuality | 1 | 1998 | 295 | 0.030 |
Why?
|
| Research | 1 | 2004 | 1977 | 0.030 |
Why?
|
| Carbon | 2 | 1989 | 672 | 0.030 |
Why?
|
| Influenza in Birds | 2 | 2006 | 76 | 0.030 |
Why?
|
| Birds | 2 | 2006 | 165 | 0.030 |
Why?
|
| Prognosis | 3 | 2021 | 29963 | 0.030 |
Why?
|
| Neuropsychological Tests | 2 | 2006 | 7121 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 6844 | 0.030 |
Why?
|
| Exostoses | 1 | 1975 | 30 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2018 | 585 | 0.030 |
Why?
|
| Zimbabwe | 1 | 2015 | 135 | 0.030 |
Why?
|
| Methotrexate | 1 | 2002 | 1718 | 0.030 |
Why?
|
| Age Factors | 2 | 2018 | 18401 | 0.030 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 2 | 2006 | 117 | 0.030 |
Why?
|
| Heterozygote | 1 | 2001 | 2794 | 0.030 |
Why?
|
| Prevalence | 2 | 2008 | 15851 | 0.030 |
Why?
|
| Massachusetts | 2 | 2016 | 8890 | 0.030 |
Why?
|
| HIV Protease Inhibitors | 1 | 2016 | 430 | 0.030 |
Why?
|
| Benchmarking | 1 | 2020 | 1056 | 0.030 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2006 | 2183 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1999 | 716 | 0.030 |
Why?
|
| Spondylitis, Ankylosing | 1 | 1975 | 158 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2000 | 3621 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2005 | 2912 | 0.030 |
Why?
|
| Developing Countries | 1 | 2006 | 2911 | 0.030 |
Why?
|
| Phenotype | 2 | 2001 | 16718 | 0.030 |
Why?
|
| Mammography | 1 | 2004 | 2431 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2000 | 986 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2006 | 3446 | 0.030 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1997 | 542 | 0.030 |
Why?
|
| Antirheumatic Agents | 1 | 2002 | 1379 | 0.020 |
Why?
|
| Birth Weight | 2 | 1999 | 2122 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 1993 | 685 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2012 | 6873 | 0.020 |
Why?
|
| El Salvador | 1 | 1991 | 34 | 0.020 |
Why?
|
| Endometrial Neoplasms | 1 | 2001 | 1381 | 0.020 |
Why?
|
| Lung Neoplasms | 3 | 1998 | 13491 | 0.020 |
Why?
|
| Tanzania | 2 | 2006 | 1406 | 0.020 |
Why?
|
| Toxoplasmosis | 1 | 1991 | 94 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1999 | 2710 | 0.020 |
Why?
|
| Wisconsin | 1 | 2010 | 122 | 0.020 |
Why?
|
| Uganda | 1 | 2015 | 1353 | 0.020 |
Why?
|
| Bipolar Disorder | 1 | 2007 | 5130 | 0.020 |
Why?
|
| Young Adult | 4 | 2021 | 59980 | 0.020 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2010 | 155 | 0.020 |
Why?
|
| Alleles | 1 | 2000 | 6893 | 0.020 |
Why?
|
| Registries | 1 | 2005 | 8351 | 0.020 |
Why?
|
| Sulfur Dioxide | 1 | 1989 | 178 | 0.020 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 1988 | 36 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 1999 | 4247 | 0.020 |
Why?
|
| Asbestos | 1 | 1991 | 250 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 1997 | 1061 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 1993 | 2227 | 0.020 |
Why?
|
| Rwanda | 1 | 2011 | 671 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 1993 | 1364 | 0.020 |
Why?
|
| Alcohol Drinking | 2 | 2013 | 4045 | 0.020 |
Why?
|
| Sampling Studies | 1 | 1989 | 614 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2010 | 327 | 0.020 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 59548 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 2000 | 3721 | 0.020 |
Why?
|
| Accidents, Home | 1 | 1988 | 73 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 1512 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 1992 | 771 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 12250 | 0.020 |
Why?
|
| Silicosis | 1 | 1986 | 47 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2002 | 3778 | 0.020 |
Why?
|
| Eating | 1 | 2013 | 1541 | 0.020 |
Why?
|
| Containment of Biohazards | 1 | 2006 | 39 | 0.020 |
Why?
|
| Antipsychotic Agents | 2 | 2015 | 3078 | 0.020 |
Why?
|
| Psychotic Disorders | 1 | 2001 | 3275 | 0.020 |
Why?
|
| Depression | 1 | 2005 | 8234 | 0.020 |
Why?
|
| Animals | 5 | 2013 | 168965 | 0.020 |
Why?
|
| Health Promotion | 1 | 2017 | 2210 | 0.020 |
Why?
|
| Ethics, Medical | 1 | 1991 | 785 | 0.020 |
Why?
|
| Family Health | 1 | 2010 | 1254 | 0.020 |
Why?
|
| Maximal Expiratory Flow Rate | 1 | 1984 | 42 | 0.020 |
Why?
|
| Accidents, Traffic | 1 | 1991 | 818 | 0.020 |
Why?
|
| Forced Expiratory Flow Rates | 1 | 1984 | 75 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2020 | 4854 | 0.010 |
Why?
|
| Respiratory Function Tests | 2 | 1986 | 1695 | 0.010 |
Why?
|
| Overweight | 1 | 2016 | 2448 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 10748 | 0.010 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1996 | 2538 | 0.010 |
Why?
|
| Maximum Allowable Concentration | 1 | 1983 | 64 | 0.010 |
Why?
|
| Genotype | 1 | 1998 | 13035 | 0.010 |
Why?
|
| Hong Kong | 1 | 2003 | 170 | 0.010 |
Why?
|
| Multivariate Analysis | 2 | 1996 | 12069 | 0.010 |
Why?
|
| Morbidity | 1 | 1988 | 1754 | 0.010 |
Why?
|
| Communicable Disease Control | 2 | 2004 | 856 | 0.010 |
Why?
|
| Patient Isolation | 1 | 2003 | 101 | 0.010 |
Why?
|
| Singapore | 1 | 2003 | 300 | 0.010 |
Why?
|
| Cities | 1 | 2004 | 542 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2015 | 8732 | 0.010 |
Why?
|
| Spirometry | 1 | 1984 | 928 | 0.010 |
Why?
|
| Quarantine | 1 | 2003 | 186 | 0.010 |
Why?
|
| Longevity | 1 | 1988 | 1083 | 0.010 |
Why?
|
| Contact Tracing | 1 | 2003 | 274 | 0.010 |
Why?
|
| Lead Poisoning | 1 | 1983 | 323 | 0.010 |
Why?
|
| Disaster Planning | 1 | 2006 | 557 | 0.010 |
Why?
|
| Malaria | 1 | 1990 | 1246 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 6513 | 0.010 |
Why?
|
| Lung | 2 | 1989 | 10076 | 0.010 |
Why?
|
| Tuberculosis | 1 | 2011 | 2011 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1985 | 1278 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2006 | 1886 | 0.010 |
Why?
|
| Health Behavior | 1 | 2009 | 2650 | 0.010 |
Why?
|
| Lead | 1 | 1983 | 882 | 0.010 |
Why?
|
| Physicians | 1 | 2015 | 4593 | 0.010 |
Why?
|
| Placebos | 1 | 2001 | 1660 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 5886 | 0.010 |
Why?
|
| Burns | 1 | 1988 | 1902 | 0.010 |
Why?
|
| Heel | 1 | 1975 | 38 | 0.010 |
Why?
|
| Elbow | 1 | 1975 | 130 | 0.010 |
Why?
|
| Health Policy | 1 | 2006 | 2698 | 0.010 |
Why?
|
| Wrist | 1 | 1975 | 231 | 0.010 |
Why?
|
| RNA | 1 | 2003 | 2715 | 0.010 |
Why?
|
| Knee | 1 | 1975 | 277 | 0.010 |
Why?
|
| Humerus | 1 | 1975 | 273 | 0.010 |
Why?
|
| Pelvic Bones | 1 | 1975 | 274 | 0.010 |
Why?
|
| Forearm | 1 | 1975 | 427 | 0.010 |
Why?
|
| Infant, Low Birth Weight | 1 | 1996 | 871 | 0.010 |
Why?
|
| Occupations | 2 | 1984 | 516 | 0.010 |
Why?
|
| Foot | 1 | 1975 | 576 | 0.010 |
Why?
|
| Leukemia | 1 | 1999 | 1518 | 0.010 |
Why?
|
| Thoracic Vertebrae | 1 | 1975 | 613 | 0.010 |
Why?
|
| Leg | 1 | 1975 | 1087 | 0.010 |
Why?
|
| Hand | 1 | 1975 | 910 | 0.010 |
Why?
|
| Aging | 2 | 1986 | 8729 | 0.010 |
Why?
|
| Age of Onset | 1 | 1996 | 3344 | 0.010 |
Why?
|
| Cervical Vertebrae | 1 | 1975 | 978 | 0.000 |
Why?
|
| Syndrome | 1 | 1975 | 3271 | 0.000 |
Why?
|
| Immunization Schedule | 1 | 1990 | 228 | 0.000 |
Why?
|
| Femur | 1 | 1975 | 1321 | 0.000 |
Why?
|
| Immunization, Secondary | 1 | 1990 | 373 | 0.000 |
Why?
|
| Vital Capacity | 1 | 1989 | 996 | 0.000 |
Why?
|
| Dust | 1 | 1989 | 488 | 0.000 |
Why?
|
| National Health Programs | 1 | 1990 | 443 | 0.000 |
Why?
|
| Brazil | 1 | 1990 | 1250 | 0.000 |
Why?
|
| Lumbar Vertebrae | 1 | 1975 | 1885 | 0.000 |
Why?
|
| Radiography | 1 | 1975 | 6975 | 0.000 |
Why?
|
| Immunity | 1 | 1990 | 1002 | 0.000 |
Why?
|
| Employment | 1 | 1989 | 1110 | 0.000 |
Why?
|
| Connecticut | 1 | 1983 | 365 | 0.000 |
Why?
|
| Edetic Acid | 1 | 1983 | 277 | 0.000 |
Why?
|
| Blood Cell Count | 1 | 1983 | 404 | 0.000 |
Why?
|
| Hematocrit | 1 | 1983 | 622 | 0.000 |
Why?
|
| Program Evaluation | 1 | 1990 | 2505 | 0.000 |
Why?
|
| Hemolysis | 1 | 1983 | 417 | 0.000 |
Why?
|
| Anemia | 1 | 1983 | 1514 | 0.000 |
Why?
|
| Chronic Disease | 1 | 1983 | 9362 | 0.000 |
Why?
|
| Cross-Sectional Studies | 1 | 1986 | 26325 | 0.000 |
Why?
|
| Neoplasms | 1 | 1985 | 22350 | 0.000 |
Why?
|